CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV
- Balanced immune response with strong induction of binding, and neutralizing antibodies and first indications of T cell activation
- Quality of immune response comparable to recovered COVID-19 patients, closely mimicking immune response after natural COVID-19 infection
- CVnCoV generally well tolerated across tested dose range of 2-12µg
- Data support 12µg dose for pivotal Phase 2b/3 clinical trial
- On track to initiate pivotal Phase 2b/3 before end of 2020
CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive interim data from its ongoing Phase 1 dose-escalation study evaluating the safety, reactogenicity and immunogenicity of CVnCoV, its investigational SARS-CoV-2 vaccine candidate. The vaccine candidate was generally well tolerated across all tested doses (2-12µg) and induced strong binding and neutralizing antibody responses in addition to first indication of T cell activation. CureVac intends to provide a detailed Phase 1 data overview and publication in a scientific journal in the coming weeks. CVnCoV is currently also being investigated in a Phase 2a clinical trial in older adults in Peru and Panama.